Europe provides €172m for research into innovative medicines

The second wave of medical research projects funded by the European Union’s largest biopharmaceutical public-private partnership was announced in Brussels on 8 March. The eight programmes aim to develop new treatments for cancer, rheumatoid arthritis, and infectious diseases.

The €172m (£147m; $238m) cost of the projects is being provided by the EU’s Innovative Medicines Initiative (www.imi.europa.eu/), a partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations.

Commenting on the latest funding, Máire Geoghegan-Quinn, the European …